In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood (vero_greenwood).
This article highlighted REC-3565, an investigational drug candidate. Greenwood’s piece quoted Ray, who expressed his excitement about a molecule he and his colleagues at Recursion had been developing: REC-3565, a MALT1 inhibitor.
